Collegium Q3 revenue $209.4M (+31% YoY); raises 2025 guidance

COLLEGIUM PHARMACEUTICAL, INC

2025-Q3 EPS reported $1.28 vs consensus $2.08 ▼ miss (-38.6%)

GAAP net income $31.5M ($0.84 diluted EPS); adj. net income $87.3M ($2.25 adj. EPS).
Record Jornay PM revenue $41.8M; prescriptions up 20% YoY; pain portfolio $167.6M (+11%).
Full-year 2025 revenue guidance raised to $775-785M; adj. EBITDA guidance $460-470M.
Ended Q3 with $285.9M cash; Board authorized $150M share repurchase through Dec 2026.
Adjusted EBITDA $133.0M, up 27% YoY; generated $78.4M cash from operations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.